MedPath

Safety and efficacy of Shaoma Zhijing granule in the treatment of tic disorder in children: a multicenter phase IV clinical trial

Phase 4
Recruiting
Conditions
Tic Disorder
Registration Number
ITMCTR2200005755
Lead Sponsor
Jiangsu Hospital of traditional Chinese Medicine, Beijing Anding Hospital Affiliated to Capital Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Meet the diagnostic criteria of Western medicine for tic disorder in children, including Tourette syndrome and chronic tic disorder;
2.TCM syndrome differentiation belongs to the syndrome of liver hyperactivity, wind movement and internal disturbance of phlegm and fire;
3.Age = 5 years old and = 18 years old, regardless of gender;
4.The guardians of the children agree to participate in this study and sign the informed consent form. At the same time, the children = 8 years old need to sign the informed consent form together.

Exclusion Criteria

1. Complicated with serious diseases such as heart, brain, liver, kidney or hematopoietic system; Children with clinically significant ECG abnormalities assessed by the investigator;
2. Abnormal liver and kidney function (ALT or AST = 1.2 times the upper limit of normal value, Cr > the upper limit of normal value);
3. Children who have been clearly diagnosed as depression and schizophrenia at the time of screening;
4. Chinese and Western drugs regularly used for the treatment of tic disorder in children within the first two weeks of screening;
5. Children allergic to Shaoma Zhijing granule and its components;
6. The researcher considers it inappropriate to participate in the clinical trial.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
YGTSS;
Secondary Outcome Measures
NameTimeMethod
TCM syndrome curative effect;
© Copyright 2025. All Rights Reserved by MedPath